The INDSWFTLAB.NS stock jumped 8.24% pre-market to INR 132.20 on 07 Feb 2026 as traders position ahead of Ind-Swift Laboratories Limited’s scheduled earnings on 10 Feb 2026. Volume surged to 8,772,157.00 shares, nearly 42.30 times the average, signaling heavy interest in the Healthcare-listed API maker on the NSE. We flag valuation, margin data and upcoming catalysts so investors can weigh price reaction against fundamentals. Meyka AI provides model-based forecasts and a proprietary grade to frame the outlook.
INDSWFTLAB.NS stock: Pre-market move and earnings setup
Ind-Swift Laboratories (INDSWFTLAB.NS) opened the pre-market session at INR 123.50 and hit INR 137.45 intraday before settling near INR 132.20, a +8.24% move versus the previous close. One-day change of +10.06 points reflects short-term buying ahead of the 10 Feb 2026 earnings announcement. Traders should note the unusually high volume of 8,772,157.00 shares indicates event-driven positioning rather than steady accumulation.
Earnings timeline and what to expect
Management will report results on or around 10 Feb 2026; market focus will include margin trends and export recovery. Recent operating data show net profit margin 28.57% and EPS INR 34.49, so expectations center on revenue beat or EPS guidance changes. Watch for commentary on API order book, regulatory approvals and contract manufacturing demand; any positive surprises could extend the pre-market rally.
We link company disclosures and the NSE quote page for filing and timing confirmation: Ind-Swift website and NSE quote.
INDSWFTLAB.NS stock: Financials and valuation
Ind-Swift shows strong balance-sheet metrics: PE 3.83, PB 0.83, current ratio 4.03, and cash per share INR 53.11. Market cap stands at INR 10,789,047,968.00 with shares outstanding 81,611,558.00. The company’s ROE is 23.62%, and net income per share is INR 33.75, supporting the low PE multiple relative to the Healthcare sector average PE ~38.71. These ratios point to value-style characteristics but also raise questions about sustainability of margins and future free cash flow conversion.
Technical picture and trading signals
Short-term momentum shows mixed signals: RSI at 39.89 and MACD histogram slightly negative, implying limited follow-through despite the pre-market spike. Price averages are 50-day INR 99.06 and 200-day INR 98.72, placing the current INR 132.20 well above moving averages on a short-term basis. Traders should monitor support near INR 122.50 (day low) and resistance at the year high INR 137.45 for intraday scaling and stop placement.
Risks, catalysts and sector context
Key risks include contract renewals, regulatory changes and margin pressure from raw-material cost swings. The Drug Manufacturers – Specialty & Generic industry remains sensitive to regulatory and export cycles; Ind-Swift’s low debt (debt/equity 0.02) reduces balance-sheet risk, but operational risk remains. Sector comparisons show the Healthcare group trades at materially higher multiples, so any earnings miss could trigger a sharp re-rating.
Meyka AI grade and price forecasts
Meyka AI rates INDSWFTLAB.NS with a score out of 100: 71.38 / Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year target INR 114.81 and a 3-year target INR 132.38, with the short-term caveat that models rely on current inputs and are not guarantees. Use these figures as model-based context alongside company updates.
Final Thoughts
The INDSWFTLAB.NS stock rally in pre-market trade to INR 132.20 on 07 Feb 2026 reflects event-driven positioning ahead of the 10 Feb 2026 earnings report. Fundamentals show a low PE of 3.83, robust ROE 23.62%, and a strong current ratio 4.03, which support a value case. Meyka AI’s forecast model projects a 1-year level of INR 114.81, implying a -13.15% downside versus the current price, while the 3-year forecast INR 132.38 implies a marginal +0.14% upside. Our proprietary grade (B+, score 71.38) balances valuation attractiveness against execution and sector risks. Investors should watch quarter results for margin commentary, order-book updates and management guidance. Forecasts are model-based projections and not guarantees, so combine them with the company’s earnings release and real-time market reactions for trading or investment decisions.
FAQs
When does Ind-Swift report earnings and how does that affect INDSWFTLAB.NS stock?
Ind-Swift is scheduled to report on 10 Feb 2026. Earnings can move INDSWFTLAB.NS stock sharply; beats may extend the pre-market rally, while misses could trigger a re-rating given the company’s low PE and high expectations.
What are the key valuation metrics for INDSWFTLAB.NS?
Key metrics: PE 3.83, PB 0.83, EPS INR 34.49, current ratio 4.03 and market cap INR 10,789,047,968.00. These show deep value versus the Healthcare sector but depend on earnings sustainability.
What price levels should traders watch around the earnings event?
Watch support at INR 122.50 (day low) and resistance near INR 137.45 (year high). Short-term stops should consider volatility and the elevated volume seen pre-market.
How reliable is the Meyka AI forecast for INDSWFTLAB.NS stock?
Meyka AI’s forecasts are model-based and include a 1-year figure INR 114.81. These are projections, not guarantees. Use them with company disclosures and market signals when planning trades or investments.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)